Blackstone acquires leading Japan drug trials company
Blackstone’s private equity funds are to acquire a 60% majority stake in CMIC, one of Japan’s leading contract research organisations (CRO) with CMIC Holdings retaining the remaining 40% ownership of the drug trials company.

